Skip to main content

Disc Medicine, Inc.

For the period ended Dec 31, 2025. Filed Feb 26, 2026.

View on SEC.gov

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2025 · Filed Feb 26, 2026

IRON$81.26+3.0%Stored close · as of Nov 9, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits
Contents

Consolidated Balance Sheets

December 31,2025December 31,2024
Assets
Current assets:
Cash and cash equivalents$91,145$192,434
Marketable securities700,007297,447
Prepaid expenses and other current assets12,7463,734
Total current assets803,898493,615
Property and equipment, net1,159751
Right-of-use assets, operating leases1,0961,569
Other assets726838
Total assets$806,879$496,773
Liabilities and Stockholders’ Equity
Current liabilities:
Accounts payable$9,018$7,948
Accrued external research and development expenses11,4517,141
Other accrued expenses15,5618,097
Operating lease liabilities, current611130
Total current liabilities36,64123,316
Long-term debt, net29,15928,322
Operating lease liabilities, non-current1,2531,548
Total liabilities67,05353,186
Commitments and contingencies (Note 14)
Stockholders’ equity:
Preferred stock, $0.0001 par value; 10,000,000 shares authorized, no shares issued or outstanding as of December 31, 2025 and December 31, 2024——
Common stock, $0.0001 par value; 100,000,000 shares authorized as of December 31, 2025 and December 31, 2024; 37,890,616 and 29,865,030 shares issued and outstanding as of December 31, 2025 and December 31, 2024, respectively43
Additional paid-in capital1,249,043741,297
Accumulated other comprehensive income965289
Accumulated deficit(510,186)(298,002)
Total stockholders’ equity739,826443,587
Total liabilities and stockholders’ equity$806,879$496,773
ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.